Data from Atossa’s Phase 2 EVANGELINE Clinical Trial to be Presented at AACR Annual Meeting
Atossa Therapeutics, Inc. is set to present data from the 40mg pharmacokinetic (PK) run-in cohort of its Phase 2 EVANGELINE study at the upcoming American Association for Cancer Research (AACR) Annual Meeting. The event will take place from April 5-10, 2024, in San Diego, California. The EVANGELINE study focuses on investigating (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with Estrogen Receptor positive (ER+) / Human Epidermal Growth Factor Receptor 2 negative (HER2-) breast cancer.
Atossa Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines to address significant unmet medical needs, particularly in breast cancer therapy. With a keen focus on breast cancer research, the company aims to offer novel treatment options for patients who lack effective alternatives.
This significant announcement follows another recent development from Atossa Therapeutics. The company reported the full enrollment of the (Z)-endoxifen arm in the Phase 2 I-SPY 2 clinical trial. The trial is evaluating (Z)-endoxifen, Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer.
These milestones highlight Atossa Therapeutics’ commitment to advancing treatments for breast cancer patients. By exploring the potential of (Z)-endoxifen as a neoadjuvant therapy, the company strives to improve the prognosis and quality of life for individuals diagnosed with ER+ breast cancer. The neoadjuvant approach aims to shrink tumors before surgery, potentially increasing the success of subsequent treatments and enhancing long-term outcomes.
Presentation of the Phase 2 EVANGELINE study data at the AACR Annual Meeting offers an exciting opportunity for Atossa Therapeutics to share its research findings with the broader scientific and medical community. The gathering of leading oncology experts at this esteemed event allows for valuable discussions and potential collaborations to accelerate progress in breast cancer therapeutics.
Comments